Clive Mason | Programme Director, AMR
LifeArc

Dr Clive Mason joined LifeArc in August 2023 to take on the role of Programme Director, AMR in the Global Health Team. Clive is also the LifeArc lead within the recently announced AMR-focused initiative called ‘PACE’ (Pathways to Antimicrobial Clinical Efficacy, https://paceamr.org.uk/ ). PACE was established to fund and support early innovative therapeutic and diagnostic approaches to meet the challenge of AMR.  Clive also supports other AMR-focused and Global Health initiatives within LifeArc. Clive has 25 years’ experience in biotechnology and drug discovery across a range of therapeutic areas. His most recent role was as VP, Anti-Infectives Research at Summit Therapeutics following their acquisition of Discuva Ltd (of which Clive was a founder). Discuva Ltd was established to develop and deploy a proprietary technology to enable the discovery and development of novel, new mechanism antimicrobials to address rising resistance to established classes of antibiotics. Through these roles Clive has contributed to the progression of a number of innovative antimicrobial agents; including a clinical stage asset, Ridinilazole (a novel DNA-minor groove binder) as a selective agent to treat and reduce recurrence of CDI, and SMT-738, a novel lipoprotein transport (lolCDE) inhibitor targeting Enterobacteriaceae.  Through his work Clive has developed a passion for finding solutions to meet the threat posed by AMR. He is an advocate for policy change to incentivise the discovery and development of AMR products and was previously a board member of the BEAM Alliance (https://beam-alliance.eu/). Clive obtained his Ph.D in Biological Sciences from the University of Warwick, UK.